Table 2: Major Cholesteryl Ester Transfer Protein Inhibitors and Clinical Trial Outcomes.
| CETP Inhibitor | Trial | Dose | n | Change in LDL-C | Change in HDL-C | Change in Lp(a) | Change in ApoB | Outcome |
|---|---|---|---|---|---|---|---|---|
| Torcetrapib | ILLUMINATE15 | 60 mg | 15,067 | -25% | +72% | NR | -15% | ↑ Mortality (off-target toxicity) |
| Dalcetrapib | Dal-OUTCOMES16 | 600 mg | 15,871 | -5% | +31–40% | No change | No change | Neutral |
| Anacetrapib | REVEAL18 | 100 mg | 30,449 | -17%* | +104% | -25% | -18% | ↓9% MACE after 4 years; Extended follow-up further 20% reduction in coronary events |
| Evacetrapib | ACCELERATE17 | 130 mg | 12,092 | -31% | +133% | -22.3% | -15.5% | Neutral |
*LDL-C estimation with the beta quantification method in a randomly selected trial subpopulation of 2000. ApoB = apolipoprotein B; CETP = cholesteryl ester transfer protein; Lp(a) = lipoprotein a; MACE = major adverse cardiovascular events; NR = not reported.